 Christine Walsh
Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 19 | 2024 | 488 | 4.810 |
Why?
| | Endometrial Neoplasms | 7 | 2022 | 163 | 1.920 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2024 | 90 | 1.560 |
Why?
| | Adenocarcinoma, Clear Cell | 3 | 2016 | 14 | 1.110 |
Why?
| | BRCA2 Protein | 3 | 2021 | 53 | 0.960 |
Why?
| | Maintenance Chemotherapy | 2 | 2024 | 22 | 0.950 |
Why?
| | Neoplasms, Glandular and Epithelial | 5 | 2017 | 35 | 0.920 |
Why?
| | BRCA1 Protein | 2 | 2015 | 63 | 0.770 |
Why?
| | Myeloproliferative Disorders | 1 | 2021 | 26 | 0.760 |
Why?
| | Cystadenocarcinoma, Serous | 5 | 2016 | 68 | 0.720 |
Why?
| | Phthalazines | 1 | 2020 | 39 | 0.700 |
Why?
| | Indazoles | 1 | 2020 | 67 | 0.690 |
Why?
| | Deoxycytidine | 1 | 2021 | 167 | 0.680 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2024 | 959 | 0.680 |
Why?
| | Bevacizumab | 1 | 2020 | 132 | 0.680 |
Why?
| | Neoplasm Staging | 8 | 2021 | 1294 | 0.660 |
Why?
| | Cisplatin | 1 | 2021 | 299 | 0.640 |
Why?
| | Piperidines | 1 | 2020 | 191 | 0.630 |
Why?
| | Medical Oncology | 2 | 2020 | 273 | 0.620 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 513 | 0.610 |
Why?
| | Piperazines | 1 | 2020 | 334 | 0.600 |
Why?
| | Gynecology | 1 | 2020 | 175 | 0.590 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 274 | 0.550 |
Why?
| | Thromboplastin | 1 | 2017 | 75 | 0.550 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2023 | 33 | 0.530 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 763 | 0.500 |
Why?
| | Genetic Testing | 2 | 2017 | 430 | 0.500 |
Why?
| | Genital Neoplasms, Female | 2 | 2015 | 81 | 0.500 |
Why?
| | Venous Thrombosis | 1 | 2017 | 161 | 0.490 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1579 | 0.440 |
Why?
| | Cystadenocarcinoma, Papillary | 2 | 2008 | 5 | 0.380 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2011 | 11 | 0.370 |
Why?
| | Female | 32 | 2024 | 68842 | 0.370 |
Why?
| | Genes, BRCA2 | 3 | 2023 | 24 | 0.370 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2014 | 2074 | 0.360 |
Why?
| | Genes, BRCA1 | 3 | 2023 | 32 | 0.360 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1196 | 0.360 |
Why?
| | Ovariectomy | 4 | 2023 | 139 | 0.360 |
Why?
| | Internship and Residency | 1 | 2020 | 1060 | 0.350 |
Why?
| | Carcinoma, Endometrioid | 1 | 2010 | 47 | 0.350 |
Why?
| | Aged, 80 and over | 13 | 2021 | 7128 | 0.340 |
Why?
| | DNA Repair | 1 | 2011 | 211 | 0.330 |
Why?
| | Venous Thromboembolism | 1 | 2013 | 277 | 0.330 |
Why?
| | Platinum | 2 | 2021 | 44 | 0.310 |
Why?
| | Uniparental Disomy | 1 | 2008 | 7 | 0.310 |
Why?
| | Aged | 18 | 2021 | 22282 | 0.310 |
Why?
| | Loss of Heterozygosity | 1 | 2008 | 46 | 0.310 |
Why?
| | Survival Rate | 5 | 2021 | 1904 | 0.300 |
Why?
| | Middle Aged | 20 | 2021 | 31322 | 0.300 |
Why?
| | Homologous Recombination | 2 | 2020 | 23 | 0.300 |
Why?
| | CA-125 Antigen | 2 | 2021 | 15 | 0.280 |
Why?
| | Humans | 33 | 2024 | 130305 | 0.280 |
Why?
| | Neoplasms | 1 | 2021 | 2467 | 0.270 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 61 | 0.260 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2078 | 0.260 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2005 | 55 | 0.240 |
Why?
| | Prognosis | 5 | 2022 | 3830 | 0.240 |
Why?
| | Drug Approval | 1 | 2024 | 88 | 0.220 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1433 | 0.220 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 205 | 0.210 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2023 | 13 | 0.210 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 389 | 0.210 |
Why?
| | Adult | 18 | 2021 | 35711 | 0.210 |
Why?
| | United States | 4 | 2024 | 14110 | 0.210 |
Why?
| | Disease-Free Survival | 3 | 2013 | 658 | 0.200 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 95 | 0.190 |
Why?
| | Indoles | 1 | 2024 | 379 | 0.190 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 40 | 0.190 |
Why?
| | Computing Methodologies | 1 | 2020 | 2 | 0.180 |
Why?
| | Survival Analysis | 2 | 2017 | 1293 | 0.180 |
Why?
| | Thrombocytosis | 2 | 2014 | 6 | 0.180 |
Why?
| | Benzamides | 1 | 2021 | 195 | 0.180 |
Why?
| | Mutation | 3 | 2023 | 3723 | 0.180 |
Why?
| | Breast Neoplasms | 2 | 2023 | 2139 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 3 | 2023 | 2282 | 0.170 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1711 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 186 | 0.160 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 766 | 0.160 |
Why?
| | DNA, Neoplasm | 2 | 2011 | 162 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 174 | 0.150 |
Why?
| | Carcinoma in Situ | 2 | 2016 | 45 | 0.150 |
Why?
| | Enzyme Multiplied Immunoassay Technique | 1 | 2017 | 2 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 621 | 0.140 |
Why?
| | Genetic Counseling | 1 | 2017 | 72 | 0.140 |
Why?
| | Remission Induction | 1 | 2017 | 270 | 0.140 |
Why?
| | Salpingectomy | 1 | 2016 | 13 | 0.130 |
Why?
| | Uterine Neoplasms | 2 | 2009 | 101 | 0.130 |
Why?
| | Vaginal Neoplasms | 1 | 2016 | 12 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 755 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2016 | 14675 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 87 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 383 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2017 | 3369 | 0.120 |
Why?
| | Medicare | 1 | 2020 | 740 | 0.120 |
Why?
| | Lymph Node Excision | 1 | 2016 | 168 | 0.120 |
Why?
| | Promoter Regions, Genetic | 2 | 2010 | 1207 | 0.110 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 130 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2021 | 10341 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2016 | 469 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2017 | 647 | 0.100 |
Why?
| | Time Factors | 3 | 2021 | 6615 | 0.100 |
Why?
| | Prefrontal Cortex | 1 | 2016 | 297 | 0.100 |
Why?
| | Adenocarcinoma | 2 | 2011 | 916 | 0.100 |
Why?
| | Brain Mapping | 1 | 2016 | 568 | 0.100 |
Why?
| | Health Care Reform | 1 | 2013 | 100 | 0.100 |
Why?
| | Endometrial Hyperplasia | 1 | 2011 | 11 | 0.100 |
Why?
| | Terminal Care | 1 | 2015 | 239 | 0.090 |
Why?
| | Executive Function | 1 | 2016 | 423 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 78 | 0.090 |
Why?
| | Los Angeles | 1 | 2010 | 63 | 0.090 |
Why?
| | MutL Protein Homolog 1 | 1 | 2010 | 12 | 0.090 |
Why?
| | Microsatellite Instability | 1 | 2010 | 37 | 0.080 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 140 | 0.080 |
Why?
| | Hysterectomy | 2 | 2007 | 118 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 77 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1051 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1015 | 0.070 |
Why?
| | Conization | 1 | 2007 | 1 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3185 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2007 | 54 | 0.070 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 398 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2013 | 580 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 773 | 0.070 |
Why?
| | Fertility | 1 | 2007 | 163 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4961 | 0.060 |
Why?
| | Risk Factors | 3 | 2023 | 9865 | 0.060 |
Why?
| | Incidence | 3 | 2021 | 2657 | 0.060 |
Why?
| | Nuclear Proteins | 1 | 2010 | 652 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 610 | 0.060 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 234 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1121 | 0.060 |
Why?
| | Neoplasm Grading | 2 | 2016 | 282 | 0.060 |
Why?
| | Age Factors | 1 | 2010 | 3153 | 0.050 |
Why?
| | Mass Screening | 1 | 2010 | 1139 | 0.050 |
Why?
| | Cohort Studies | 4 | 2016 | 5431 | 0.050 |
Why?
| | Algorithms | 1 | 2010 | 1638 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1537 | 0.050 |
Why?
| | Young Adult | 2 | 2016 | 12404 | 0.040 |
Why?
| | Mammography | 1 | 2021 | 139 | 0.040 |
Why?
| | California | 1 | 2021 | 403 | 0.040 |
Why?
| | Population Surveillance | 2 | 2013 | 429 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 350 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 1300 | 0.030 |
Why?
| | Anisotropy | 1 | 2016 | 70 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 270 | 0.030 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2016 | 95 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 94 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2639 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2016 | 285 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2016 | 319 | 0.030 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 212 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2021 | 979 | 0.030 |
Why?
| | White Matter | 1 | 2016 | 132 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 328 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2016 | 256 | 0.030 |
Why?
| | Attention | 1 | 2016 | 438 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1442 | 0.020 |
Why?
| | Hospice Care | 1 | 2015 | 199 | 0.020 |
Why?
| | Advance Care Planning | 1 | 2015 | 206 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 736 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 869 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2016 | 1004 | 0.020 |
Why?
| | Premenopause | 1 | 2011 | 127 | 0.020 |
Why?
| | Health Personnel | 1 | 2017 | 649 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1974 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2011 | 165 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 387 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 948 | 0.020 |
Why?
| | Carboplatin | 1 | 2009 | 140 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1341 | 0.020 |
Why?
| | Brachytherapy | 1 | 2009 | 103 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1510 | 0.020 |
Why?
| | Paclitaxel | 1 | 2009 | 216 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1341 | 0.020 |
Why?
| | Parity | 1 | 2007 | 121 | 0.020 |
Why?
| | Medical Records | 1 | 2007 | 171 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2014 | 2732 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1219 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5400 | 0.010 |
Why?
| | Pregnancy Outcome | 1 | 2007 | 381 | 0.010 |
Why?
| | Reoperation | 1 | 2007 | 558 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2015 | 1986 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1235 | 0.010 |
Why?
| | Pregnancy | 1 | 2007 | 6301 | 0.010 |
Why?
| | Male | 1 | 2016 | 63748 | 0.000 |
Why?
|
|
Walsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|